Factors contributing to ribavirin-induced anemia
| Autor: | Eiji Kajiwara, Tamotsu Mukai, Hiromi Ishibashi, Masashi Higashi, Junya Shimono, Hideyuki Nomura, Nobuyuki Yamashita, Masanori Nagano, Seizaburo Kashiwagi, Hironori Tanimoto, Toshihiro Maruyama, Yutaka Matsui, Jun Hayashi |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male Hemolytic anemia Anemia Hemolytic medicine.medical_specialty Combination therapy Anemia Interferon alpha-2 Antiviral Agents Gastroenterology Hemoglobins chemistry.chemical_compound Risk Factors Internal medicine Ribavirin Humans Medicine Aged Univariate analysis Dose-Response Relationship Drug Hepatology business.industry Interferon-alpha Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease Recombinant Proteins chemistry Immunology Toxicity Drug Therapy Combination Female Hemoglobin business Follow-Up Studies |
| Zdroj: | Journal of Gastroenterology and Hepatology. 19:1312-1317 |
| ISSN: | 1440-1746 0815-9319 |
| DOI: | 10.1111/j.1440-1746.2004.03459.x |
| Popis: | Background and Aim: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia. This study was conducted to identify the factors contributing to ribavirin-induced anemia. Methods: Eighty-eight patients with chronic hepatitis C who received interferon-α-2b at a dose of 6 MU administered intramuscularly for 24 weeks in combination with ribavirin administered orally at a dose of 600 mg or 800 mg participated in the study. A hemoglobin concentration of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text